Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Retained Earnings (2016 - 2025)

Protalix BioTherapeutics has reported Retained Earnings over the past 16 years, most recently at -$385.0 million for Q4 2025.

  • Quarterly results put Retained Earnings at -$385.0 million for Q4 2025, down 1.75% from a year ago — trailing twelve months through Dec 2025 was -$385.0 million (down 1.75% YoY), and the annual figure for FY2025 was -$385.0 million, down 1.75%.
  • Retained Earnings for Q4 2025 was -$385.0 million at Protalix BioTherapeutics, down from -$378.4 million in the prior quarter.
  • Over the last five years, Retained Earnings for PLX hit a ceiling of -$374.9 million in Q4 2021 and a floor of -$389.9 million in Q4 2022.
  • Median Retained Earnings over the past 5 years was -$381.5 million (2023), compared with a mean of -$381.9 million.
  • Biggest five-year swings in Retained Earnings: fell 7.94% in 2021 and later grew 2.13% in 2023.
  • Protalix BioTherapeutics' Retained Earnings stood at -$374.9 million in 2021, then fell by 3.98% to -$389.9 million in 2022, then rose by 2.13% to -$381.5 million in 2023, then rose by 0.83% to -$378.4 million in 2024, then dropped by 1.75% to -$385.0 million in 2025.
  • The last three reported values for Retained Earnings were -$385.0 million (Q4 2025), -$378.4 million (Q4 2024), and -$381.5 million (Q4 2023) per Business Quant data.